Exhibit 99.1 News Release For more information contact: Media Relations: Sophia Marshall Senior Vice President, Communications Fiserv, Inc. 678-641-0116 sophia.marshall@fiserv.com Investor Relations: Julie Chariell Senior Vice President, Investor Relations Fiserv, Inc. 332-282-2685 julie.chariell@fiserv.com For Immediate Release Fiserv Reports Third Quarter 2025 Results GAAP revenue growth of 1% in the quarter and 5% year to date; GAAP EPS increased 49% in the quarter and 29% year to date; Organic revenue g ...

Exhibit 99.1 Fiserv Reports Third Quarter 2025 Results GAAP revenue growth of 1% in the quarter and 5% year to date; GAAP EPS increased 49% in the quarter and 29% year to date; Organic revenue growth of 1% in the quarter and 5% year to date; Adjusted EPS decreased 11% in the quarter and increased 6% year to date; Company now expects 2025 organic revenue growth of 3.5 to 4% and adjusted EPS of $8.50 to $8.60 Launches One Fiserv action plan to prioritize and enhance client focus and build on Fiserv's strength ...

OppFi . Q3 2025 Earnings Presentation October 29, 2025 Disclaimer This presentation the "Presentablem" in Copy"in, or the "Company" is for ritornalism purposes only Ceftain information contained heren has been peried from soss sreased or the eleadel or the ourgoses used teenin, the Company makes no recreasmation or waranty with research of such information. Tredenarks and taske rannes referend by in this Pr owners. The information contained herein does not purport to be all-inclusive. This Presentation does ...

Exhibit 99.1 COASTAL FINANCIAL CORPORATION ANNOUNCES THIRD QUARTER 2025 RESULTS Company Release: October 29, 2025 Everett, WA – Coastal Financial Corporation (Nasdaq: CCB) (the "Company", "Coastal", "we", "our", or "us"), the holding company for Coastal Community Bank (the "Bank"), through which it operates a community-focused bank segment ("community bank") with an industry leading banking as a service ("BaaS") segment ("CCBX"), today reported unaudited financial results for the quarter ended September 30, ...

"Our growth in media spend this quarter reflects steady progress on our strategy with strong execution. Our ability to deliver measurable outcomes across channels continues to differentiate Criteo and build momentum," said Michael Komasinski, Chief Executive Officer of Criteo. "We are advancing rapidly in innovation, leveraging our deep commerce data and AI to position Criteo at the forefront of agentic AI and deliver sustainable shareholder value." Operating Highlights • Criteo's media spend2 was $4.3 bill ...

Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K CURRENT REPORT Registrant's telephone number, including area code: (612) 605-6625 Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2025 JAMF HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 001-39399 82-3031543 (State or other jurisdiction of incorporation) 100 Washington Ave S, Suite 900 Minneapolis, MN 55401 (Addre ...

Financial Performance - Collaboration revenue for the three months ended September 30, 2025, was $0, compared to $80,000,000 for the same period in 2024, indicating a significant drop[19] - Net loss for the three months ended September 30, 2025, was $19,595,000, compared to a net loss of $21,696,000 for the same period in 2024, showing an improvement of about 9.7%[19] - For the nine months ended September 30, 2025, the company reported a net loss of $54.546 million compared to a net income of $6.843 million in the same period of 2024[25] - The net loss for the nine months ended September 30, 2025, was $54.5 million, compared to a net income of $6.8 million for the same period in 2024, primarily due to $80.0 million of collaboration revenue recognized in 2024[101] - The company has incurred significant operating losses since inception and expects to continue incurring losses over the next several years[156] Assets and Liabilities - Total current assets decreased from $249,923,000 as of December 31, 2024, to $205,863,000 as of September 30, 2025, a decline of approximately 17.7%[16] - Cash and cash equivalents decreased from $58,212,000 as of December 31, 2024, to $47,078,000 as of September 30, 2025, a decrease of approximately 19.1%[16] - Total liabilities decreased from $17,684,000 as of December 31, 2024, to $16,492,000 as of September 30, 2025, a reduction of about 6.7%[16] - Stockholders' equity decreased from $243,034,000 as of December 31, 2024, to $198,366,000 as of September 30, 2025, a decline of approximately 18.4%[16] - As of September 30, 2025, total cash equivalents and marketable securities amounted to $200,404,000, a decrease from $241,021,000 as of December 31, 2024[43][44] Operating Expenses - Total operating expenses for the nine months ended September 30, 2025, were $62,076,000, down from $82,468,000 in the same period of 2024, representing a reduction of approximately 24.7%[19] - General and administrative expenses for the nine months ended September 30, 2025, were $21,389,000, down from $28,732,000 in the same period of 2024, a decrease of approximately 25.6%[19] - The company recorded total operating expenses of $21,858,000 for the three months ended September 30, 2025, down from $25,126,000 in the same period of 2024[94] - Total operating expenses decreased by $20.4 million from $82.5 million in the nine months ended September 30, 2024 to $62.1 million in the same period in 2025[127] Research and Development - Research and development expenses for the three months ended September 30, 2025, were $14,296,000, slightly down from $14,639,000 in the same period of 2024[19] - Research and development expenses fell by $11.0 million from $51.7 million in the nine months ended September 30, 2024 to $40.7 million in the same period in 2025, mainly due to decreased external research and employee compensation costs[131] - External research and development expenses for pociredir were $5.4 million for the three months ended September 30, 2025, compared to $2.2 million in the same period in 2024[113] Cash Flow - Net cash used in operating activities was $43.267 million for the nine months ended September 30, 2025, a significant decrease from $14.543 million provided in the same period of 2024[25] - The company expects its cash and marketable securities to be sufficient to fund operating expenses for at least 12 months from the date of the financial statements[32] - The company had $200.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, which is expected to fund operations into 2028[104] Stock and Equity - Weighted-average common shares outstanding, basic, increased from 62,409,000 for the three months ended September 30, 2024, to 62,597,000 for the same period in 2025[19] - The company has reserved 28,952,871 shares of common stock for future issuance as of September 30, 2025, an increase from 26,673,185 shares as of December 31, 2024[52] - The total number of outstanding stock options increased to 11,870,785 with a weighted average exercise price of $6.57[61] Collaboration Agreements - The Company entered into a collaboration and license agreement with Sanofi in May 2024, which included an upfront payment of $80.0 million, but was terminated in April 2025[69][70] - The Company recognized no revenue associated with the Sanofi Agreement during the nine months ended September 30, 2025[74] - Collaboration revenue dropped by $80.0 million from $80.0 million in the nine months ended September 30, 2024 to $0 in the same period in 2025, due to the termination of the Sanofi collaboration agreement[128] Clinical Development and Risks - The successful development of product candidates remains uncertain, with no revenue expected from product sales for several years[105] - The company is still in the early stages of product development and has not completed development of any product candidates[156] - The company may face limitations on utilizing its net operating losses and research and development tax credit carryforwards due to an ownership change deemed to have occurred on September 12, 2024[176] - The company is subject to risks related to the lengthy and expensive clinical drug development process, which may not yield successful outcomes[184] - The company may need to conduct additional clinical trials or testing if initial results are not positive, which could delay marketing approvals[189] Market and Competition - Competition in the pharmaceutical industry is substantial, with major companies potentially developing products more successfully or rapidly[212] - Recent FDA approvals for competitive products, such as CASGEVY and LYFGENIA, could impact the company's market position[214] - The company may need to price its products at a significant premium over generic alternatives, affecting market acceptance and sales[214]

Highlights (All comparisons are against the prior year period unless otherwise noted) NORTHBROOK, IL, October 29, 2025 - IDEX Corporation (NYSE: IEX) today announced its financial results for the three-month period ended September 30, 2025. "Our IDEX teams executed well in the third quarter, delivering solid results in an uncertain macroeconomic environment. We are focused squarely on what we can control as we leverage our 8020 approach to drive momentum within our growth platforms. Our teams are effectivel ...

Exhibit 99.1 For more information, contact: Investor Relations Media Contact Stan Kovler Amy Aylward 919/595-4196 603/952-5138 Investor_relations@extremenetworks.com pr@extremenetworks.com Extreme Networks Reports First Quarter Fiscal Year 2026 Financial Results Q1 revenue up 15% year-over-year, marking sixth consecutive quarter of sequential growth SaaS ARR up 24% YoY Morrisville, NC, October 29, 2025 -- Extreme Networks, Inc. ("Extreme") (Nasdaq: EXTR) today released financial results for its first quarte ...

- TRYNGOLZA® generated $32 million in net product sales in the third quarter 2025 - - DAWNZERA™ (donidalorsen) launch of to encouraging start - - Olezarsen significantly reduced triglycerides and acute pancreatitis events in severe hypertriglyceridemia (sHTG) in landmark Phase 3 studies; sNDA submission on track by year-end – - Positive pivotal zilganersen results in Alexander disease position Ionis for first independent neurology launch in 2026 - Exhibit 99.1 Ionis reports third quarter 2025 financial resu ...